AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente

Form 483 issued March 19, 2021 · Frederick, Maryland

Observations
3
Pages
4
FEI number
3002617771

In short: On March 19, 2021, FDA issued a Form 483 with 3 observations to AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente in Frederick, Maryland (FEI 3002617771). The investigators were Meense Viviana Matta, Viviana Matta and Zhao Wang. Most observations concern quality system and production.

At a glance

2 of 3 observations on this 483 concern quality system.

Quality system2
Production1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    The responsibilities of the quality control unit are not in…

  2. 02

    Your firm has failed to establish adequate microbial control for®®…

  3. 03

    Your firm has failed to thoroughly investigate deviations/nonconformities and OOS results to ensure its investigations identify…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente?

FDA listed 3 observations on this Form 483, mostly about quality system and production. The opening words of each observation are shown on this page.

Who inspected AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente?

Meense Viviana Matta, Viviana Matta and Zhao Wang are named on this Form 483. Each investigator has a profile showing what they cite most.

When was AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente inspected by FDA?

This Form 483 is dated March 19, 2021.

How do I get the full Form 483 for AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free